Alzheimer's disease, Nat Rev Dis Primers, vol.1, p.15056, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01723790
Alzheimer's disease, Lancet, vol.388, pp.505-522, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01723790
The amyloid hypothesis of Alzheimer's disease at 25 years, EMBO Mol Med, vol.8, issue.6, pp.595-608, 2016. ,
Targeting the beta secretase BACE1 for Alzheimer's disease therapy, Lancet Neurol, vol.13, issue.3, pp.319-348, 2014. ,
Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease, Arch Neurol, vol.69, issue.11, pp.1430-1470, 2012. ,
A phase 3 trial of semagacestat for treatment of Alzheimer's disease, N Engl J Med, vol.369, issue.4, pp.341-50, 2013. ,
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease, N Engl J Med, vol.370, issue.4, pp.311-332, 2014. ,
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease, N Engl J Med, vol.370, issue.4, pp.322-355, 2014. ,
The antibody aducanumab reduces A? plaques in Alzheimer's disease, Nature, vol.537, issue.7618, pp.50-56, 2016. ,
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects, J Neurochem, vol.130, issue.1, pp.4-28, 2014. ,
BACE1 physiological functions may limit its use as therapeutic target for Alzheimer's disease, Trends Neurosci, vol.39, issue.3, pp.158-69, 2016. ,
Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-a beta-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer's disease, J Med Chem, vol.59, issue.23, pp.10435-50, 2016. ,
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS betaamyloid in animal models and in Alzheimer's disease patients, Sci Transl Med, vol.8, issue.363, pp.363-150, 2016. ,
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease, N Engl J Med, vol.378, issue.18, pp.1691-703, 2018. ,
BACE inhibition by verubecestat produces a rapid, non-progressive reduction in brain and hippocampal volume in Alzheimer's disease, J Prev Alzheimers Disease, vol.5, issue.4, pp.18-27, 2018. ,
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease, Neurology, vol.34, issue.7, pp.939-983, 1984. ,
, Diagnostic and statistical manual of mental disorders, 2000.
Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, vol.12, issue.3, pp.189-98, 1975. ,
The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults, Am J Psychiatry, vol.168, issue.12, pp.1266-77, 2011. ,
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia, Neurology, vol.44, issue.12, pp.2308-2322, 1994. ,
Interventions to prevent falls in older adults: updated evidence report and systematic review for the US Preventive Services Task Force, JAMA, vol.319, issue.16, pp.1705-1721, 2018. ,
Risk factors associated with falls in older adults with dementia: a systematic review, Physiother Can, vol.69, issue.2, pp.161-70, 2017. ,
Meta-analysis of the impact of 9 medication classes on falls in elderly persons, Arch Intern Med, vol.169, issue.21, pp.1952-60, 2009. ,
Fall-risk-increasing drugs: a systematic review and metaanalysis: II. Psychotropics, J Am Med Dir Assoc, vol.19, issue.4, pp.371-382, 2018. ,
A complex relationship between suicide, dementia, and amyloid: a narrative review, Front Neurosci, vol.12, p.371, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02320316
, Suicidal ideation and behavior: prospective assessment of occurrence in clinical trials, 2019.
, BACE inhibitor BI 1181181 voluntarily put on temporary clinical hold for safety evaluation, BACE-Inhibitor-BI-1181181-Voluntarily-Put-on-Temporary-Clinical-Hold-for-Safety-Evaluation.html. Accessed 4, 2015.
Pharmacological BACE1 and BACE2inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice, Sci Rep, vol.6, p.21917, 2016. ,
BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells, Proc Natl Acad Sci, vol.110, issue.26, pp.10658-63, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-02328958
The potent BACE1 inhibitor LY2886721 elicits robust central A? pharmacodynamic responses in mice, dogs, and humans, J Neurosci, vol.35, issue.3, pp.1199-210, 2015. ,
Update on Janssen's BACE Inhibitor Program, 2019. ,
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis, Lancet Neurol, vol.11, issue.3, pp.241-250, 2012. ,
BACE inhibition by verubecestat produces a rapid non-progressive reduction in brain and hippocampal volume in Alzheimer's disease, JPAD, vol.5, p.19, 2018. ,
Effects of A? immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease, Neurology, vol.64, issue.9, pp.1563-72, 2005. ,
Changes in brain volume with bapineuzumab in mild to moderate Alzheimer's disease, J Alzheimers Dis, vol.49, issue.4, pp.1123-1157, 2016. ,
Randomized trial of verubecestat for prodromal Alzheimer's disease, N Engl J Med, vol.380, issue.15, pp.1408-1428, 2019. ,
Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease, N Engl J Med, vol.380, issue.15, pp.1483-1488, 2019. ,
Lowering of amyloid-beta by ?-secretase inhibitors -some informative failures, N Engl J Med, vol.380, issue.15, pp.1476-1484, 2019. ,
, Publisher's Note
, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations